Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rein Therapeutics (RNTX) Shares Outstanding (Diluted Average) (2021 - 2025)

Rein Therapeutics (RNTX) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $24.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 44.85% to $24.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.2 million, a 44.85% increase, with the full-year FY2024 number at $17.9 million, up 290.09% from a year prior.
  • Shares Outstanding (Diluted Average) was $24.2 million for Q3 2025 at Rein Therapeutics, roughly flat from $24.2 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $90.5 million in Q2 2021 to a low of $4.4 million in Q4 2021.
  • A 5-year average of $19.6 million and a median of $6.5 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): plummeted 94.98% in 2022, then surged 338.47% in 2024.
  • Rein Therapeutics' Shares Outstanding (Diluted Average) stood at $4.4 million in 2021, then increased by 2.23% to $4.5 million in 2022, then increased by 1.31% to $4.6 million in 2023, then soared by 290.09% to $17.9 million in 2024, then surged by 34.74% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Shares Outstanding (Diluted Average) are $24.2 million (Q3 2025), $24.2 million (Q2 2025), and $21.9 million (Q1 2025).